Krispy Kreme Inc vs TransMedics Group Inc — how do they compare? Krispy Kreme Inc trades at $3.12 (market cap $544.79M), while TransMedics Group Inc trades at $89.69 (market cap $3.07B). The key difference: TransMedics Group Inc is far larger — about 5.6× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| DNUT | TMDX | |
|---|---|---|
Market Cap | $544.79M | $3.07B |
Sector | Consumer Staples | Technology |
52-Week High | $4.70 | $150.42 |
52-Week Low | $2.92 | $61.99 |
Enterprise Value | $1.79B | $3.46B |
Dividend Yield | 3.47% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TMDX trades at $83.89, up 4.59% today, with a bullish technical signal from moving averages and strong support at $81. The company reported a Q2 2026 earnings miss ($0.44 actual vs. $0.50 expected) but beat revenue expectations, with 2025 net income at $190.29M. Analyst consensus is a Buy with a $99.57 price target, though recent news highlights a legal investigation into fiduciary duties.
Outlook remains positive due to raised revenue guidance and institutional interest, but risks include earnings volatility, margin pressure, and legal scrutiny. The stock's valuation multiples suggest growth expectations, yet execution on cost control and international expansion will be critical for sustained upside.
Trailing returns across standard periods
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →